| Oct 10 |
Immatics stock falls as it looks to raise $150M via public offering
|
| Oct 10 |
Immatics Announces Proposed $150 Million Public Offering
|
| Oct 10 |
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
|
| Oct 9 |
Immatics N.V. (IMTX) Receives Buy Rating from Analysts
|
| Oct 4 |
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
|
| Sep 16 |
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
|
| Sep 6 |
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
|
| Aug 15 |
Immatics Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 13 |
Immatics GAAP EPS of -€0.17, revenue of €18.8M
|
| Aug 13 |
Immatics Announces Second Quarter 2024 Financial Results and Business Update
|
